Skip to main content
Menu
US

HTRF Kinase Binding Kit Streptavidin Eu-Conjugate, 20,000 Assay Points

​This Streptavidin-Eu cryptate is used in the HTRF® Kinase Binding format, in combination with an N-terminal-biotinylated Kinase and red-fluorescent tracers.

For research use only. Not for use in diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption and disposal requirements under European REACH regulations (EC 1907/2006).

Feature Specification
Application Biochemical Enzymatic Assay

​This Streptavidin-Eu cryptate is used in the HTRF® Kinase Binding format, in combination with an N-terminal-biotinylated Kinase and red-fluorescent tracers.

For research use only. Not for use in diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption and disposal requirements under European REACH regulations (EC 1907/2006).

Product Variants
Unit Size: 1,000 Assay Points
Part #:
62KBSAKAF
List Price
USD 262.25
Unit Size: 20,000 Assay Points
Part #:
62KBSAKAB
List Price
USD 1,911.00

Overview

The ​Streptavidin was labeled with Eu crypate. Biotin binds to Streptavidin with high affinity (Ka=10^15 M-1). This binding is rapid and stable, making it an ideal choice for use in the biochemical HTRF Kinase Binding platform.​

Specifications

Application
Biochemical Enzymatic Assay
Brand
HTRF
Detection Modality
HTRF
Product Group
Fluorescent Reagent
Shipping Conditions
Shipped in Dry Ice
Target Class
Kinases
Technology
TR-FRET
Therapeutic Area
Metabolism/Diabetes
Neuroscience
Oncology & Inflammation
Unit Size
20,000 Assay Points

Video gallery

How it works

Kd determination assay principle

​The binding of the tracers is detected in a sandwich assay format using Streptavidin labeled with Europium Cryptate (donor), which binds to the N-terminal biotinylated-Kinase, and a red fluorescent tracer labelled with d2 (acceptor). The detection principle is based on HTRF® technology. The HTRF ratio (665/620) will increase upon the addition of more of the tracer, and will saturate depending on the dissociation constant (Kd) of the tracer to the N-terminal biotinylated-Kinase.

1kinase-binding-how-it-works-assay-principal-saturation-staurosporine-red-62kb01redc-62kb01rede.svg

 

Kd determination assay protocol

Saturation binding experiments on the three tracers (i.e. Staurosporine-Red, Dasatinib-Red, and Sunitinib-Red) can be run in 96- or 384-well plates (20 µL final volume). First, a dilution series of tracer ranging between 0 and 1 µM in the Kinase Binding Buffer is prepared in a 96-well non-binding plate. NExt, 5 µL of Kinase Binding Buffer are dispensed into the final 96- or 384-well plate. Then 5 µL of N-terminal biotinylated-Kinase are added, followed by 5 µL of Streptavidin Eu-cryptate. Finally 5 µL of the red tracer solution are added. The HTRF ratio is measured after 1 H of incubation.

2kinase-binding-how-it-works-assay-protocol-saturation-staurosporine-red-62kb01redc-62kb01rede.svg

 

IC50/Ki determination assay principle

Principle of HTRF® Kinase binding assay (IC50/Ki-determination). The binding of the tracers is detected in a sandwich assay format using Streptavidin labeled with Europium Cryptate (donor), which binds to the tagged Kinase, and a red fluorescent tracer labelled with d2 (acceptor). The detection principle is based on HTRF® technology. The HTRF ratio (665/620) will increase upon the addition of more of the tracer, and will saturate depending on the dissociation constant (Kd ) of the tracer to the tagged kinase. When an inhibitor of the kinase is added, the tracer will be displaced and the HTRF signal will disappear, depending on the dose.

10kinase-binding-how-it-works-assay-principal-inhibition-anti-gst-eu-62kbgstkab-62kbgstkaf.svg

 

IC50/Ki determination assay protocol

​​Pharmacological evaluation of inhibitors of interest can be run in 96- or 384-well plates. First, a dilution series of inhibitor ranging between 40 µM and 0.23 nM is prepared, and 5 µL of each concentration are dispensed into the plate. Next, 5 µL of tagged-Kinase are added, followed by 5 µL of Streptavidin Eu-cryptate. Finally, 5 µL of tracer solution are added, prepared at 4x the final concentration. The HTRF ratio is measured after 1H of incubation. Analyses of the data give typical dose response curves ranging between 10 µM and 56 pM, enabling an evaluation of the IC50/Ki values for the inhibitor of interest.

2kinase-binding-how-it-works-assay-protocol-saturation-staurosporine-red-62kb01redc-62kb01rede.svg

 

Assay validation

Saturation Binding KIT-Biotin

​A typical saturation binding experiment is performed using final tracer concentrations between 0 and 250 nM, and measuring total- and non-specific binding signals. Subtracting the non-specific from the total binding signal gives the specific signal, which can be analysed to give the Kd. Here an example is shown where the best tracer for inhibitor studies proved to be Sunitinib-Red, with a Kd of 22 nM on 5 nM KIT-BTN. ​​

20assay-validation-kinase-binding-streptavidin-eu-1.svg

 

Competitive Binding KIT-Biotin

​D​ose response curves of various known kinase inhibitors (Staurosporine, Dasatinib, PP2, Imatinib, Tozasertib, Sunitinib, Gefitinib, and Sorafenib) were measured using Sunitinib-Red at its Kd (22 nM) on 5 nM KIT-BTN. Dasatinib and Sunitinib showed high potencies, in good correlation with literature values. As expected, Gefitinib does not bind to KIT.

 

6assay-validation-kinase-binding-anti-gst-eu-2.svg

 

Resources

Are you looking for resources, click on the resource type to explore further.

1-1 of 1 Resources
Guide Icon
Guide
HTRF solutions, guide to major applications

This guide provides you an overview of HTRF applications in several therapeutic areas.

Scroll Icon